永利yl8886官方网站

  1. 新闻资讯

永利yl8886官方网站与沪亚生物国际达成一项2.82亿美元重大交易!

2020-08-25 永利yl8886官方网站
      近日,永利yl8886官方网站(苏州)有限公司,一家专注于开发环球领先的小分子抗肿瘤药物的生物技术公司,与沪亚生物国际达成一项独家许可协议。永利yl8886官方网站将其SHP2抑制剂GH21中国以外的产品开发和商业化权利授予沪亚生物国际,沪亚生物国际将为此支付首付及里程碑款高达2.82亿美元,永利yl8886官方网站还将获得GH21产品在海外上市后的销售提成。
      永利yl8886官方网站CEO王奎锋博士表示,“SHP2是一个被证实极具潜力的抗肿瘤靶点,抑制SHP2预期能使众多肿瘤患者获益。临床前研究数据表明,勤浩研发的SHP2抑制剂GH21,具有体内外活性强、口服代谢性质优良和安全性好的特点,即将在环球开展临床试验。我们很高兴能够和沪亚生物国际合作,加速推动GH21在环球主要医药市场的临床开发和商业化。
      沪亚生物国际CEO兼执行主席Mireille Gillings博士说:“我们很高兴与永利yl8886官方网站签订这项许可协议,并将如此令人兴奋和新颖的产品添加到我们优秀的肿瘤产品线中。对于更安全和更有效的癌症治疗仍存在大量未满足的医疗需求。GH21临床前研究数据超出了我们的预期,显示GH21是一个颇具前途的新型化合物,具有治疗多种肿瘤类型患者的潜力。”


关于SHP2
      SHP2是由PTPN11基因编码的非受体酪氨酸磷酸酶,也是世界上首个被发现的促癌磷酸酶。近年来SHP2受到了广泛关注,一方面,SHP2处于多数RTK下游,介导RTK至RAS-MAPK/PI3K-mTOR等细胞生长、存活关键的信号通路传导。另一方面,SHP2也处于PD1、BTLA等免疫检查点下游,介导肿瘤免疫逃逸信号。因此,SHP2可以在肿瘤靶向与肿瘤免疫中发挥双重作用,是极具潜力的抗肿瘤靶点。此外,SHP2抑制剂和包括免疫检查点药物在内的多种药物联合使用效果良好,是近年抗肿瘤领域最具市场潜力的靶点之一。
关于GH21
      GH21是永利yl8886官方网站自主开发的,具有环球知识产权的小分子SHP2抑制剂,具有极强的生物活性,且对多种SHP2点突变体有效。体内外的研究表明,GH21对SHP2以外的磷酸酶、激酶以及安全性相关的靶点无显著影响,脱靶风险低;同期间 时光谢性质优异,口服生物利用度高,且安全性良好,具有较大的安全窗,是一个极具开发潜力的小分子抗肿瘤药物。
关于永利yl8886官方网站
      永利yl8886官方网站是一家专注于环球领先的小分子抗肿瘤新药开发的生物科技公司。公司核心团队具有丰富的新药研发和企业管理经验,目前已获多家投资机构支持。永利yl8886官方网站着力打造独具特色的创新药物研发体系,着眼于环球市场,形成了以6个高价值靶向抗肿瘤品种为核心的产品管线。力求坚持基础研究、创新开发以及商业化相结合,以开放合作的企业精神,快速推进研究成果产业化,最终惠及广大患者。
 
关于沪亚国际生物
      沪亚生物国际是加快源自中国的创新药产品环球开发的领导者,促进在国际市场上更快、更具成本效益和更低风险的药物开发。通过与生物制药、学术和商业机构的广泛合作,沪亚生物国际已经建立了覆盖所有治疗领域的最大的中国来源的化合物组合。公司在美国、日本、韩国、加拿大、爱尔兰及中国八个战略城市设有办公室,已成为加快产品开发和实现环球价值最大化的首选合作伙伴。欲了解更多信息,请访问www.huyabio.com

 

GenHouse reaches a major deal with HUYABIO $282M!
GenHouse Pharmaceuticals (Suzhou) Ltd. Co., a biotechnology company focusing on the development of the world’s leading small molecule anti-cancer drugs, has recently reached an exclusive license agreement with HUYA Biosciences International (HUYABIO). GenHouse granted the product development and commercialization rights of the SHP2 inhibitor GH21 outside of China to HUYABIO, who will pay upfront and milestone payments up to 282 million dollars, and GenHouse will also receive royalty payment for overseas GH21 product sales.
Dr. Kuifeng Wang, CEO of GenHouse, said that “SHP2 is a proven anti-tumor target with great potential, and its inhibition is expected to benefit many cancer patients. Data from preclinical studies show that the SHP2 inhibitor GH21 developed by GenHouse has the characteristics of strong in vivo and in vitro activities with excellent oral metabolism and good safety; clinical trials will be launched globally. We are very pleased to cooperate with HUYABIO to accelerate the clinical development and commercialization of GH21 in major global pharmaceutical markets."
Dr. Mireille Gillings, CEO and Executive Chair of HUYA Bioscience said, "We are delighted to conclude this licensing agreement with Genhouse and add such an exciting and novel product to our excellent oncology pipeline. There is a large unmet need for safer and more effective cancer treatments. GH21 data from preclinical studies have exceeded our expectations, indicating it is a promising novel compound that has the potential to treat cancer patients across many tumor types”
 
About SHP2
SHP2 is a non-receptor tyrosine phosphatase encoded by the PTPN11 gene, and it is also the first cancer-promoting phosphatase discovered in the world. In recent years, SHP2 has received widespread attention, on the one hand, SHP2 is downstream of most RTKs, mediating RTK to RAS-MAPK/PI3K-mTOR and other key signaling pathways for cell growth and survival. On the other hand, SHP2 is also downstream of immune checkpoints of PD1 and BTLA, and mediates tumor immune escape signals. Therefore, SHP2 can play a dual role in tumor targeting and tumor immunity, and is a potential  anti-tumor target. In addition, the combination of SHP2 inhibitors and multiple drugs including immune checkpoint drugs has excellent effects, and it is one of the most promising targets in the anti-tumor field in recent years.
About GH21
GH21, independently developed by GenHouse Pharmaceuticals with global intellectual property rights. It has strong biological activity and is effective against a variety of SHP2 point mutants. In vivo and vitro studies have shown that GH21 has no significant effects on any other phosphatases, kinases or safety related targets other than SHP2 with low off-target risks; in the meantime, it has excellent metabolism properties ,high oral bioavailability, excellent safety profile, relatively wide safety window and great development potential as a small molecule anti-tumor drug.
About GenHouse Pharmaceuticals (Suzhou) Ltd. Co.
GenHouse Pharmaceuticals is a biotechnology company focusing on the development of world’s leading anti-tumor small molecules. The core team of the company has extensive experience in new drug research and development and corporate management, has received supports from multiple investment firms. GenHouse Pharmaceutical strives to create a unique and innovative drug R&D system, focusing on the global market and forming a product pipeline with 6 high-value targeted anti-tumor varieties as the core. The company strives to adhere to the combination of basic research, innovative development, and commercialization, and quickly advance the industrialization of research results with the entrepreneurial spirit of open cooperation, and ultimately benefit the patients.
 
About HUYA Bioscience International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in international markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally. For more information please visit www.huyabio.com.